Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-07-28 Sale |
2025-07-30 5:57 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $20.46 | $66,504 | 134,556 (Direct) |
View |
| 2025-07-21 Sale |
2025-07-23 6:52 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,500 | $22.29 | $278,646 | 952,688 (Indirect) |
View |
| 2025-07-17 Sale |
2025-07-21 7:21 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,500 | $22.52 | $281,518 | 940,392 (Indirect) |
View |
| 2025-07-10 Sale |
2025-07-14 5:07 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.66 | $22,655 | 137,806 (Direct) |
View |
| 2025-07-07 Sale |
2025-07-09 7:29 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $19.79 | $131,951 | 296,642 (Indirect) |
View |
| 2025-06-27 Sale |
2025-07-01 4:42 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $20.91 | $67,956 | 138,806 (Direct) |
View |
| 2025-06-20 Sale |
2025-06-24 5:36 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,500 | $21.4 | $267,458 | 965,188 (Indirect) |
View |
| 2025-06-17 Sale |
2025-06-18 6:22 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,500 | $22.18 | $277,292 | 952,892 (Indirect) |
View |
| 2025-06-13 Sale |
2025-06-17 4:24 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $22.55 | $67,655 | 142,056 (Direct) |
View |
| 2025-06-09 Sale |
2025-06-11 6:25 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $20.34 | $135,574 | 303,309 (Indirect) |
View |
| 2025-06-03 Sale |
2025-06-05 4:55 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
7,500 | $20.03 | $150,220 | 977,688 (Indirect) |
View |
| 2025-06-03 Sale |
2025-06-05 4:53 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
7,500 | $20.05 | $150,352 | 965,392 (Indirect) |
View |
| 2025-05-27 Sale |
2025-05-29 5:38 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $16.18 | $52,593 | 145,056 (Direct) |
View |
| 2025-05-19 Sale |
2025-05-21 6:31 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
5,000 | $16.31 | $81,534 | 985,188 (Indirect) |
View |
| 2025-05-19 Sale |
2025-05-21 6:29 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
5,000 | $16.49 | $82,453 | 972,892 (Indirect) |
View |
| 2025-05-07 Sale |
2025-05-09 6:48 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $18.39 | $122,579 | 309,976 (Indirect) |
View |
| 2025-05-01 Sale |
2025-05-05 6:43 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
7,500 | $20.05 | $150,391 | 990,188 (Indirect) |
View |
| 2025-05-01 Sale |
2025-05-05 6:42 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
7,500 | $20.06 | $150,415 | 977,892 (Indirect) |
View |
| 2025-04-28 Sale |
2025-04-30 6:59 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $18.69 | $60,738 | 148,306 (Direct) |
View |
| 2025-04-21 Sale |
2025-04-23 5:09 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
5,000 | $16.07 | $80,366 | 997,688 (Indirect) |
View |
| 2025-04-17 Sale |
2025-04-21 5:55 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
5,000 | $16.42 | $82,096 | 985,392 (Indirect) |
View |
| 2025-04-07 Sale |
2025-04-09 4:25 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $18.04 | $120,269 | 316,643 (Indirect) |
View |
| 2025-03-27 Sale |
2025-03-31 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $21.33 | $69,321 | 151,556 (Direct) |
View |
| 2025-03-24 Sale |
2025-03-26 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.5 | $22,505 | 154,806 (Direct) |
View |
| 2025-03-19 Sale |
2025-03-21 5:49 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,500 | $20.61 | $257,575 | 1,002,688 (Indirect) |
View |
| 2025-03-17 Sale |
2025-03-19 5:42 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,500 | $20.83 | $260,320 | 990,392 (Indirect) |
View |
| 2025-03-07 Sale |
2025-03-11 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $21.44 | $142,936 | 323,310 (Indirect) |
View |
| 2025-02-27 Sale |
2025-03-03 8:07 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $20.41 | $66,327 | 155,806 (Direct) |
View |
| 2025-02-07 Sale |
2025-02-10 5:32 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $21.93 | $146,206 | 500,977 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-07-28 Exercise |
2025-07-30 5:57 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 134,556 (Direct) |
View |
| 2025-07-28 Exercise |
2025-07-30 5:57 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 134,556 (Direct) |
View |
| 2025-07-10 Exercise |
2025-07-14 5:07 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 137,806 (Direct) |
View |
| 2025-07-10 Exercise |
2025-07-14 5:07 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 137,806 (Direct) |
View |
| 2025-06-27 Exercise |
2025-07-01 4:42 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 138,806 (Direct) |
View |
| 2025-06-27 Exercise |
2025-07-01 4:42 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 138,806 (Direct) |
View |
| 2025-06-13 Exercise |
2025-06-17 4:24 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $2.48 | 142,056 (Direct) |
View |
| 2025-06-13 Exercise |
2025-06-17 4:24 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $0 | 142,056 (Direct) |
View |
| 2025-05-27 Exercise |
2025-05-29 5:38 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 145,056 (Direct) |
View |
| 2025-05-27 Exercise |
2025-05-29 5:38 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 145,056 (Direct) |
View |
| 2025-04-28 Exercise |
2025-04-30 6:59 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 148,306 (Direct) |
View |
| 2025-04-28 Exercise |
2025-04-30 6:59 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 148,306 (Direct) |
View |
| 2025-03-27 Exercise |
2025-03-31 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 151,556 (Direct) |
View |
| 2025-03-27 Exercise |
2025-03-31 7:37 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 151,556 (Direct) |
View |
| 2025-03-24 Exercise |
2025-03-26 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 154,806 (Direct) |
View |
| 2025-03-24 Exercise |
2025-03-26 7:37 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 154,806 (Direct) |
View |
| 2025-03-04 Exercise |
2025-03-06 6:02 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
10,000 | $2.48 | 155,806 (Direct) |
View |
| 2025-03-04 Exercise |
2025-03-06 6:02 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
10,000 | $0 | 155,806 (Direct) |
View |
| 2025-02-27 Exercise |
2025-03-03 8:07 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 155,806 (Direct) |
View |
| 2025-02-27 Exercise |
2025-03-03 8:07 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 155,806 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:40 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:39 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director |
15,368 | $0 | 15,368 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:38 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
23,014 | $0 | 23,014 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:36 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:35 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:34 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:33 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:32 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
171,000 | $0 | 500,977 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:29 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:28 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
490,000 | $0 | 490,000 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:27 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |